Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond

Area of Science:

• Oncology
• Radiopharmaceutical Therapy
• Drug Development

Background:

• Prostate-specific membrane antigen (PSMA) is a validated molecular target for prostate cancer.
• PSMA is highly expressed on most prostate cancer cells, making it an attractive therapeutic target.

Purpose of the Study:

• To review the landscape of emerging PSMA-based therapies for prostate cancer.
• To provide an overview of therapeutic strategies beyond 177Lu-PSMA-617.

Main Methods:

• Literature review of ongoing clinical trials and preclinical studies.
• Analysis of different PSMA-targeting modalities, including radionuclide conjugates, drug conjugates, and cellular immunotherapies.

Main Results:

• Multiple PSMA-based therapeutic approaches are in development.
• These therapies include radionuclide-based agents, cytotoxic drug conjugates, and cellular immune products.
• Each therapeutic modality presents unique advantages and disadvantages.

Conclusions:

• PSMA-targeting therapies represent a promising area for prostate cancer treatment.
• The diversity of PSMA-based agents offers potential for personalized treatment strategies.
• Further research and clinical evaluation are ongoing to optimize these therapies.